GNH USA

Europe — EMA

Meriofert Pfs

GNH USA supplies Meriofert Pfs (Follicle-Stimulating Hormone / Luteinising Hormone), a gonadotropin for infertility due to anovulation and assisted

Follicle-Stimulating Hormone, Luteinising Hormone

Request sourcing

1
Pack/s

What is Follicle-Stimulating Hormone, Luteinising Hormone?

Follicle-Stimulating Hormone / Luteinising Hormone, the active ingredient in Meriofert Pfs, is a gonadotropin presented as a sterile injectable solution for intramuscular or subcutaneous use. It treats infertility due to anovulation, supports assisted reproductive technology procedures, and manages hypogonadotropic hypogonadism in patients requiring hormonal stimulation.

GNH USA supplies Meriofert Pfs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Follicle-Stimulating Hormone, Luteinising Hormone used for?

Meriofert Pfs is a gonadotropin used in reproductive‑endocrine disorders. - Infertility due to anovulation: stimulates follicular development to enable ovulation. - Assisted reproductive technology (e.g., IVF): enhances ovarian response to improve oocyte yield. - Hypogonadotropic hypogonadism: replaces deficient gonadotropins to restore reproductive function.

What are the side effects of Follicle-Stimulating Hormone, Luteinising Hormone?

Adverse reactions may occur with any gonadotropin therapy.

Common Side Effects: - Injection site pain or erythema. - Mild abdominal discomfort. - Headache. - Nausea. - Transient ovarian hyperstimulation symptoms.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS) requiring medical attention. - Thromboembolic events. - Severe allergic reaction (anaphylaxis). - Ectopic pregnancy. - Multiple pregnancy.

What precautions apply to Follicle-Stimulating Hormone, Luteinising Hormone?

Use Meriofert Pfs only under specialist supervision and after appropriate diagnostic work‑up. - Pregnancy testing: confirm non‑pregnant status before initiating therapy. - Ovarian monitoring: perform regular ultrasound to assess follicular response. - OHSS risk: adjust dose if signs of hyperstimulation appear. - Thrombotic risk: evaluate personal or family history of clotting disorders. - Allergies: avoid if known hypersensitivity to any component. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Follicle-Stimulating Hormone, Luteinising Hormone interact with?

Drug interactions can modify the efficacy or safety of Meriofert Pfs.

Major Interactions (Avoid): - GnRH antagonists: may blunt the intended gonadotropin response. - High‑dose estrogen therapy: can interfere with follicular development.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor for increased clotting risk if OHSS occurs. - Corticosteroids: may affect hormone metabolism. - Thyroid hormone replacement: adjust dosing if thyroid status changes.

Frequently asked questions

What is Meriofert Pfs used for?+
Meriofert Pfs is a gonadotropin preparation containing follicle‑stimulating hormone and luteinising hormone. It is used to induce ovulation in women with anovulatory infertility, to support ovarian stimulation in assisted reproductive technologies such as in‑vitro fertilisation, and to replace deficient gonadotropins in hypogonadotropic hypogonadism.
How does Follicle‑Stimulating Hormone / Luteinising Hormone work in Meriofert Pfs?+
The FSH component binds to FSH receptors on ovarian granulosa cells, promoting follicle growth and estradiol production. The LH component binds to LH receptors on theca and luteal cells, stimulating androgen conversion to estrogen and supporting luteal phase function. Together they coordinate the hormonal cascade required for follicular maturation and ovulation.
What is the usual dose of Meriofert Pfs?+
The dose of Meriofert Pfs is individualized by the prescribing specialist based on the patient’s clinical profile, ovarian response monitoring, and treatment protocol. The prescriber determines the amount, frequency, and duration of administration to achieve the desired therapeutic outcome.
Is Meriofert Pfs safe to use during pregnancy or breastfeeding?+
Meriofert Pfs is intended for use before pregnancy to achieve ovulation. Its safety in established pregnancy has not been established, and it is not recommended for use during pregnancy. Limited data are available for breastfeeding; therefore, the product should be used only if the potential benefit justifies any possible risk to the infant.
How do I order Meriofert Pfs from GNH USA?+
To order Meriofert Pfs, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.
How does Meriofert Pfs compare with other fertility hormone preparations?+
Meriofert Pfs combines both FSH and LH activity in a single injectable, which can simplify dosing compared with regimens that require separate FSH and LH products. Some alternatives provide only FSH, requiring an additional LH or hCG injection for luteal support. The combined formulation may reduce injection burden while delivering comparable efficacy when used according to protocol.
What are the storage and handling requirements for Meriofert Pfs?+
Meriofert Pfs must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. If the product is inadvertently exposed to temperatures outside this range, discard it and obtain a new supply.
How is Meriofert Pfs administered?+
Meriofert Pfs is administered by a qualified healthcare professional via intramuscular or subcutaneous injection, typically into the thigh or abdomen. The injection site should be rotated according to standard clinical practice, and the dose is prepared under aseptic conditions using sterile technique.
What are the most serious risks associated with Meriofert Pfs?+
The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can be severe and require hospitalization, and rare thromboembolic events. Patients should be monitored closely for abdominal distension, rapid weight gain, shortness of breath, or severe pain, and immediate medical attention should be sought if these symptoms develop.
Who should not use Meriofert Pfs?+
Meriofert Pfs should not be used in individuals with known hypersensitivity to any component of the formulation, in patients with active ovarian cysts, uncontrolled thyroid disease, or a history of severe OHSS. It is also contraindicated in women who are already pregnant.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Follicle-Stimulating Hormone, Luteinising Hormone
Route
Intramuscular Use , Subcutaneous Use
Manufacturer
Ibsa Farmaceutici Italia
Origin
EU

Related products

A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU
A

A

Liquid Extract From Viscum Album Subsp. Abietis Var Abies Alba (1:20), Extraction Solvents: Water Fo

Helixor Heilmittel Gmbh
EU